|
|
Volumn 30, Issue 3, 2012, Pages 203-
|
|
Hedgehog hopes lifted by approval... and stung by failure
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BMS 833923;
ERISMODEGIB;
ERIVEDGE;
GEMCITABINE;
HEDGEHOG PATHWAY INHIBITOR;
LEQ 506;
MEMBRANE PROTEIN;
PF 04449913;
PLACEBO;
SARIDEGIB;
SMOOTHENED PROTEIN;
SONIC HEDGEHOG PROTEIN;
UNCLASSIFIED DRUG;
VISMODEGIB;
BASAL CELL CARCINOMA;
BIOTECHNOLOGY;
BONE CANCER;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER RESEARCH;
CHONDROSARCOMA;
DRUG APPROVAL;
DRUG INDICATION;
DRUG MECHANISM;
DRUG PROTEIN BINDING;
DRUG RESEARCH;
EMBRYO DEVELOPMENT;
FOOD AND DRUG ADMINISTRATION;
HEAD AND NECK CANCER;
HEMATOLOGIC MALIGNANCY;
HUMAN;
MAJOR CLINICAL STUDY;
MYELOFIBROSIS;
NEOPLASM;
NOTE;
PANCREAS CANCER;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SIGNAL TRANSDUCTION;
SOLID TUMOR;
TREATMENT FAILURE;
TREATMENT OUTCOME;
ANILIDES;
ANTINEOPLASTIC AGENTS;
CARCINOMA, BASAL CELL;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
HEDGEHOG PROTEINS;
HUMANS;
PYRIDINES;
SIGNAL TRANSDUCTION;
ERINACEIDAE;
|
|
EID: 84857977283
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0312-203 Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
